Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. **We look forward to being of service to you.**

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

**Phone:** +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline landscape.

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct
Reference : GMDHC11176IDB
Number of Pages : 90
Report Format : PDF
Table Of Contents for Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019 [Report Updated: 29-03-2019]

- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Juvenile Macular Degeneration (Stargardt Disease) - Overview
- Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development
- AccuCell Inc
- Allkeus Pharmaceuticals
- IncAstellas Pharma Inc
- Biophytis SAC
- Copernicus Therapeutics Inc
- Generation Bio Corp
- Gruppo Ferrer Internacional SA
- Katakiry GmbH
- Lin Bioscience Inc
- Mzence Pharmaceuticals
- Nightstar Therapeutics PLC
- ProQR Therapeutics
- WAVE Life Sciences Ltd
- WAVE Life Sciences Ltd
- Biophytis SAC
- Generation Bio Corp
- Katakiry GmbH
- Lin Bioscience Inc
- Mzence Pharmaceuticals
- Nightstar Therapeutics PLC
- ProQR Therapeutics
- WAVE Life Sciences Ltd
- WAVE Life Sciences Ltd
- Genentech Inc
- Novartis Pharma Inc
- Ophthotech Corp
- ProQR Therapeutics
- WAVE Life Sciences Ltd
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
- ACT Biopharmaceuticals
How to Buy...

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019 [Report Updated: 29-03-2019]

Option 1 - Online
Go to our website and pay online with any major debit or credit card: https://www.bioportfolio.co.uk/product/230742

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:  
Job Title:  
Your Email:  
Your Contact Phone:  
Company Name:  
Address:  
Post/Zip Code:  
Country:  
P.O. Number:  
Any Other Instructions:  

Pricing Options: (please tick one)
- $2000 | Single User Price
- $4000 | Site License Price
- $6000 | Enterprise License Price

Payment Options: (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature:  

Option 3 - Phone Us on +44 (0)1300 321501
We will be delighted to give you our personal attention.